Experts: Journavx a prescription to stem Long Island's addiction crisis
Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ ...
BioSpace3d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Vertex COO Arbuckle to step down later this year
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
The Washington Post7d
FDA approves new, non-opioid painkiller Journavx
The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain Treatment
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
Top Vertex exec to retire after more than 12 years with company
Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.
rheumatologyadvisor6d
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Vertex projects $11.75B-$12B 2025 revenue with new launches driving growth
Q4 2024 Management View CEO Reshma Kewalramani highlighted the planned leadership transitions, with Stuart Arbuckle retiring in July 2025. Charlie Wagner will take on additional responsibilities as ...
Seeking Alpha9d
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential.
USA Today10d
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The approval was announced in an FDA press release, and it will be sold under the brand name Journavx by Vertex Pharmaceuticals. This painkiller's approval reflects the FDA’s commitment to ...